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Background: In acute sepsis, reduced lipid and lipoprotein levels occur in HIV negative patients, in particular, low 
high-density lipoprotein cholesterol (HDL–c) levels are inversely correlated with sepsis severity and increased 
mortality. However, due to the limited data describing lipid and lipoprotein levels in septic HIV–infected individuals 
we aimed to investigate the changes in this subgroup. 
Materials and Methods: A prospective cross–sectional observational study of HIV–infected patients comparing 
admitted HIV – infected patients with sepsis to healthy controls from the antiretroviral therapy (ART) clinic. Non 
fasting - lipograms, ART use, diagnosis of  tuberculosis (TB), markers of infection, renal function and mortality 
outcome to 3 months post discharge were reviewed.  
Results: Total cholesterol (TC), low–density lipoprotein (LDL–c) and HDL-c were all significantly lower in the sepsis 
group (p < 0.001). HDL–c was significantly associated with a higher white cell count (p = 0.018), higher C– reactive 
protein (p = 0.036) and low serum albumin (p < 0.001). In those with active TB (55%) HDL–c was reduced even 
further (0.55 vs. 0.72mmol/L, p = 0.013). Acute kidney injury (p = 0.560) and mortality at discharge (p = 0.097) or 3 
months follow up (p = 0.953) was not associated with reduced HDL–c.  
Conclusion: Septic HIV–infected patients had significantly reduced lipid and lipoprotein levels at admission. Of note 
however, a low HDL–c was associated with markers of infection and reductions in HDL–c was more marked in those 
with active TB.  
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List of abbreviations: AKI - Acute kidney injury, ART - Antiretroviral therapy, BMI - Body mass index, CRP - C – 
reactive protein, CI - Confidence intervals, CKD – EPI - Chronic kidney disease epidemiology collaboration equation, 
eGFR - estimated glomerular filtration rate, GM – CSF - Granulocyte - monocyte colony - stimulating factor, HDL – c 
- High-density lipoprotein cholesterol, IQR - Interquartile ranges, LPS - Lipopolysaccharides, Lipoteichoic acid – LTA, 
LDL – c - Low density lipoprotein, MTB - Mycobacterium tuberculosis, SCr - Serum creatinine, TC - Total 




 Total cholesterol (TC) and triglycerides (TG) are water insoluble plasma lipid molecules, whilst low density 
lipoprotein cholesterol (LDL-c) and high-density lipoprotein cholesterol (HDL-c) are lipoproteins (Feingold 2000). 
Lipoproteins comprise a central lipid core complexed to an apolipoprotein. In patients with risk factors for 
cardiovascular disease LDL-c and HDL-c are the two lipoproteins most frequently measured, however their measured 
serum levels are seldom utilized in acute care (Feingold 2000). Despite this, there is interest in the role of lipids and, 
especially, lipoproteins in acute illness and particularly their role in sepsis (Feingold and Grunfeld 2000). Both lipid 
and lipoprotein levels decrease in those with sepsis and of all the lipoproteins the greatest inverse correlation with 
severity of sepsis appears to be reductions in HDL-c concentration (van Leeuwen et al., 2003; Chien et al., 2005; 
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with increased mortality; a 13-fold increase in risk of overall mortality at 30 days in patients with sepsis is reported in 
those with HDL-c levels less than 0.52mmol/L (Chien et al., 2005). Following recovery, levels of HDL-c increase (van 
Leeuwen et al., 2003; Chien et al., 2005; Barlage et al., 2009). 
 In acute HIV infection, TC, TG, LDL-c and HDL-c levels initially decline with a low HDL–c being the 
commonest abnormality and a mean value of 0.77mmol/L is reported in antiretroviral therapy (ART) naive African 
HIV - infected adults (Njoroge et al., 2017). However, with the introduction of ART all lipid and lipoprotein levels tend 
to increase (Fontas et al., 2004; Dave  et al., 2016;  Di Biagio et al., 2016; Taramasso et al., 2018).  
 Although the changes in lipid and lipoprotein levels in HIV-infected patients, both prior to and following ART 
initiation, are well described (Dave et al., 2016), there is limited data describing these changes in acute illness in HIV- 
infected patients. In particular, there is little data examining whether the acute changes in TC, TG, LDL – c and HDL - 
c observed in septic HIV negative patients also occur in HIV - infected individuals. We therefore examined differences 
in TC, TG, LDL–c and HDL-c levels in septic HIV-infected adults and compared them to healthy HIV-infected 
controls.  
 
Materials and Methods 
Study setting 
 
 This prospective cross–sectional observational study included two groups of patients in the months October 
2014 through June 2015, at the Tshepong Hospital, Klerksdorp, South Africa. At this facility patients are managed for a 
range of acute medical problems but, due to the significant burden of HIV and tuberculosis (TB) in the region, a large 
proportion of patients require admission for treatment of underlying opportunistic infections, with underlying active TB 
being the most common. The first group included septic HIV-infected patients admitted to the acute medical unit who 
were followed up until discharge and subsequently monthly, for three months. The second group comprised clinically 
well HIV-infected outpatients receiving ART (healthy controls) who were being followed up as part of routine care at 
the Tshepong hospital HIV outpatient clinic and enrolled during a single clinic visit. In both data sets: patients had to be 
aged 18 years or older and all consented to the use of their clinical records for research purposes. The Human Research 
Ethics Committee of the University of Witwatersrand, Johannesburg, South Africa, approved this study (Clearance 
Certificate Number: M140742). 
 
Study definitions and inclusion criteria 
 
 Amongst admitted HIV-infected inpatients, those that fulfilled the study definition of sepsis were identified 
and compared to the control group of clinically well HIV-infected individuals. Septic patients were defined as those 
admitted with any infection diagnosed by the treating internal medicine physician with the presence of both an elevated 
temperature greater than 38 degrees Celsius and admission  C–reactive protein (CRP) > 10mg/dL (Povoa et al., 2005, 
Vandijck et al., 2007; Sproston and Ashworth 2018; Gyawali et al., 2019).  
 Healthy controls were identified in the ART outpatient clinic and defined as patients requiring only their 
routine prescription for ART. Those with either constitutional symptoms suggestive of TB or in whom a clinician 
suspected an acute infection were excluded. Only those from each group who had results of a lipogram were included 
in this analysis. To avoid confounding from secondary dyslipidemia, patients in both groups with underlying diabetes, 
chronic kidney disease, hypothyroidism and known hyperlipidemia were excluded from the study, as were all those 





 From the clinical record, the prior history and duration of ART use and medical co–morbidities were 
abstracted. Patients were followed to discharge and the following were noted: whether or not a diagnosis of new TB 
disease was made during admission, the discharge diagnosis and mortality outcome at discharge. Following discharge, 
mortality outcome over three months follow up was also recorded. Laboratory results of inpatient blood samples were 
also recorded, these included: the CD4 count, HIV viral load, a complete blood count, randomly timed lipogram and 
serum biochemistry. All laboratory investigations were performed by the same laboratory, the public sector National 




 Descriptive statistics are reported as medians and interquartile ranges (IQRs) for continuous variables and for 
categorical variables as proportions with 95% confidence intervals (95% CI). We compared the sepsis patients to 
healthy HIV-infected controls, using the Chi–square test for categorical variables; Mann–Whitney–and Kruskall– 
Wallis tests for continuous variables were used. Due to the small sample size a multivariable regression analysis was 






 Of the initial 199 patients in the septic group and 156 patients in the healthy HIV-infected control group, 55 
and 21 patients were excluded, respectively (Figure 1); either they did not meet the study definition of sepsis, we 
identified the presence of an exclusionary co–morbid condition or the absence of complete lipogram results. Our final 
group was 144 sepsis and 135 healthy HIV-infected controls. The groups were well matched by age (median age of 39 
[34–39] years old in both), gender (60% vs. 68% female) and body mass index (BMI) (20.8 [18.8–23.9] vs. 20.7 [17.6 
– 24.7]kg/m
2
). 67% were receiving ART in the sepsis group and all were on ART in the HIV-infected healthy control 
group. Of those on ART, 48% in the sepsis group and all in the healthy control group were taking a tenofovir (TDF) - 
based regimen. Furthermore, the sepsis group had a smaller proportion of patients with viral suppression (38 vs. 52%) 
and a lower median CD4 count (100 [47 – 248] vs. 291 [92–501] cells/mm
3




Figure 1: Study diagram showing of sepsis vs. healthy control groups. 
. 
















 The leading infections in the septic patients included: TB (55%), gastroenteritis (30%), pneumonia (18%) and 
urinary tract infections (6%) and, of note, they had  a significantly higher serum creatinine (SCr) concentration, white 
cell count (WCC) and CRP concentration and a lower serum albumin level than the healthy control group (p < 
0.001).(Table 1). 
 
Table 1: Baseline patient characteristics in the sepsis and healthy groups 
  Sepsis (n = 144) Healthy (n = 135) 
Age (years), median(IQR) 39 (34 - 49) 39 (34 - 49) 
Ethnicity n (%)     
Black 144 (99) 132 (98) 
Mixed race 1 (1) 2 (1) 
Indian  1 (1) 1 (1) 
Gender (Female) n (%) 89 (60) 92 (68) 
ART Use n (%)     
Naïve 48 (33) 0 (0) 
TDF 69(48) 135 (100) 
Other NRTI 27 (18) 0 (0) 
NNRTI 92 (64) 114 (84) 
PI 4 (3) 21 (16) 
Newly Diagnosed TB n (%) 79 (55) 0 (0) 
CD4 (cells/mm3), median (IQR) 100 (47 - 248) 291 (92 - 501) 
VL < 1000 n (%) 54 (38) 70 (52) 
Weight (kg), median (IQR) 56 (49 - 68) 55 (45 - 66) 
BMI (kg/m2), median (IQR) 20.8 (18.8 - 23.9) 20.7 (17.6 - 24.7) 
Creatinine (umol/L), median (IQR) 216 (156 - 482) 61 (50 - 74) 
CRP (mg/L), median (IQR) 109 (48 - 192) 17 (5 - 64) 
White Cell Count (x109/L), median (IQR) 8.59 (5.74 - 13.7) 5.6 (4.6 - 8.5) 
Albumin (g/L), median (IQR) 18 (15 - 23) 35 (29 - 42) 
Duration of stay in survivors n (%)     
< 10 days 64 (44)   
> 10 days 61 (41)   
Duration of stay in deceased n (%)     
< 10 days 6 (4)   
> 10 days 15 (10)   
Outcome n (%)     
Discharge     
Recovered 123 (85)   
Deceased 21 (15)   
3 Month follow up     
Recovered 95 (64)   
Deceased 38 (26)   







TC, LDL-c and HDL-c were lower in septic patients on admission than in healthy HIV-infected controls: (2.75 [2.16 – 
3.41] vs. 3.47 [2.85 – 4.13]mmol/L; 1.29 [0.91 – 1.54] vs. 1.87 [1.33 – 2.38]mmol/L; 0.63 [0.44 – 0.88] vs. 0.93 [0.6 – 
1.28]mmol/L)  [p < 0.001], respectively. This was in contrast to TG levels which were raised in septic patients 
compared to healthy HIV-infected controls, but still within normal limits (1.68 [1.16 – 2.39] vs. 1.27 [0.86 – 























































Figure 3: Serum lipids in septic patients compared by the presence of tuberculosis (TB). 
 When the HDL – c levels in septic patients were studied in relation to infective markers: HDL -c was significantly lower in 
patients whose laboratory assays suggested an underlying infection or inflammatory process, these included: a WCC of more than 11 
x 109/L (p = 0.018), CRP greater than 30mg/L [p = 0.036] and serum albumin lower than 20g/dL [p < 0.001]. (Table 2). 
 
 
  Figure 2: Comparison of serum lipids between the sepsis vs. the healthy group. 
 Lipid levels (TC, LDL-c and HDL-c), amongst the sepsis group were all lower in those with TB compared to those without TB. 
However, only the HDL – c was significantly reduced (0.55 [0.42 – 0.73] vs. 0.72 [0.51 – 0.97]mmol/L) [p < 0.013] and correlated 




Table 2: HDL concentrations categorised by HIV immune and virological status, markers renal function, infective 
markers and hospital stay and mortality outcome. 
 
  However, when the septic group was stratified by markers of acute kidney injury (AKI) (elevated SCr and 
reduced estimated glomerular filtration rate (eGFR) calculated by the chronic kidney disease epidemiology 
collaboration equation [CKD–EPI]) no significant difference in HDL–c measures were noted [p = 0.560 and p = 0.934, 
respectively]. Moreover, even when stratified by severity of AKI, according to the Kidney Disease Improving Global 
Outcomes criteria, there was no significant reduction in HDL–c amongst septic HIV infected patients [p = 0.593] 
(Khwaja 2012).  
  HDL (median [IQR]) (mmol/L) p - value 
CD4 (cells/mm3)     
< 50 0.58 (0.39 - 0.71) 
p = 0.042 
50 – 350 0.62 (0.48 - 0.86) 
> 350 0.83 (0.51 - 1.22) 
HIV Viral Load < 1000 (copies/ml)     
< 1000 0.75 (0.55 - 1.09) 
p = 0.001 > 1000 0.54 (0.4 - 0.72) 
Creatinine (umol/L)     
< 200 0.61 (0.43 - 0.88) 
p = 0.560 > 200 0.65 (0.45 - 0.87) 
CKD - EPI (mL/min/1.73m2)     
< 30 0.63 (0.44 - 0.86) 
p = 0.934 > 30 0.61 (0.44 - 0.88) 
AKI Severity     
Mild  0.64 (0.49 - 0.99) 
p = 0.593 
Moderate 0.58 (0.42 - 0.79) 
Severe 0.64 (0.44 - 0.84) 
CRP (mg/L)     
5 to 30 0.86 (0.52 - 1.16) 
p = 0.036 Above 30 0.58 (0.44 - 0.76) 
WCC (x109/L)     
0 – 11 0.66 (0.50 -0.93) 
p = 0.018 > 11 0.53 (0.35 - 0.74) 
Albumin (g/L)     
< 20 0.55 (0.41 - 0.72) 
p < 0.001 > 20 0.77 (0.52 - 1.07) 
Duration of stay     
Survivors     
< 10 days 0.53 (0.4 - 0.86) 
p = 0.034 > 10 days 0.66 (0.48 - 0.96) 
Deceased     
< 10 days 0.60 (0.5 - 0.73) 
p = 0.205 > 10 days 0.71 (0.66 - 1.07) 
Outcome     
Discharge     
Recovered 0.58 (0.42 - 0.86) 
p = 0.097 Deceased 0.7 (0.58 - 0.99) 
3 month follow up     
Recovered 0.65 (0.5 - 0.76) 
p = 0.953 Deceased 0.66 (0.45 - 0.89) 
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 Despite high rates of mortality in the group with sepsis –15% in hospital and 24% at 3 months - reduced HDL 
– c levels were not associated with mortality either at discharge (0.58 vs 0.7mmol/L)[p = 0.097] or by the three month 
follow – up (0.65 vs. 0.66mmol/L)[p = 0.953]. In the deceased, TB was present in the vast majority both at discharge 
(71%) and at three months follow-up (71%).  
 Regarding other lipoproteins, LDL–c was significantly lower with a CRP greater than 90mg/L (1.125mmol/L 
[IQR: 0.81–1.52] vs. 1.395mmol/L [IQR: 0.94 – 1.82], [p = 0.03] but no other significant associations between markers 
of infection, AKI or mortality were noted for LDL -c, TC or TG. 
    
Discussion 
 
 In this study of HIV-infected adults, we compared those admitted to hospital with sepsis to a group of healthy 
controls. We describe significant reductions in HDL–c, LDL–c and TC but not TG levels in septic patients compared to 
the healthy control group. We report high rates of active TB (55%) and, of note, HDL–c was significantly lower in 
patients with newly diagnosed TB and in those where markers suggested infection or inflammation. However, no 
association was noted between HDL-c levels, AKI or mortality.  
 The lower levels of TC, LDL–c and HDL–c in HIV - infected patients with sepsis is similar to trends noted in 
septic HIV - negative patients where rapid decline in serum TC, LDL–c and HDL–c occurs at onset of sepsis, however 
TG changes are variable as noted by the opposing changes reported (Dunham et al., 2003; van Leeuwen et al., 2003; 
Chien et al. 2005; Tanaka et al., 2017). Of all, it is a declining HDL–c, and its potential beneficial role in sepsis, that is 
best described (Morin et al., 2015). Amongst septic HIV negative individuals it is proposed that the lipid rich walls of 
gram negative (lipopolysaccharides) [LPS] and gram positive (lipoteichoic acid) [LTA] bacteria are neutralised by 
HDL–c and cleared by reverse cholesterol transport with resultant low HDL-c concentrations (Morin et al., 2015). 
Furthermore, HDL–c attenuates the immune response from both macrophages and endothelial cells through binding of 
LPS (Morin et al., 2015). However, reduced levels of apolipoprotein A, due to diminished secretion, also occur in 
sepsis and may contribute to noted HDL-c reductions (van Leeuwen et al., 2003). Reduced LDL–c levels are postulated 
to occur due to clearance of bacterial toxins by LDL–c. This occurs through LDL–c first binding to LPS which are then 
subsequently cleared by hepatic LDL–c receptors (Khovidhunkit et al., 2004; Guirgis et al., 2018). The reduced levels 
of LDL–c and HDL–c we note suggest that similar mechanisms, amongst HIV negative patients, resulting in reduced 
LDL–c and HDL–c may occur in HIV-infected individuals with acute sepsis, however, further clarification of these 
mechanisms are necessary. Elevations in TG we note are similarly noted in other studies, TG increases are postulated to 
occur due to increased hepatic very low density lipoprotein (VLDL) production stimulated by pro–inflammatory 
cytokines which are increased in sepsis (Khovidhunkit  et al.,  2004).  
 In HIV negative patients the acute decrease in HDL–c during sepsis is negatively correlated with a rise in 
inflammatory cytokines: tumour necrosis factor–alpha, interleukin 6 and interleukin 10. Conversely, a positive 
correlation between declining HDL – c and serum albumin is noted (Chien et al., 2005; Vavrova et al., 2016). 
Likewise, in septic HIV-infected patients we observe similar relationships between HDL–c and CRP–a surrogate 
marker for inflammatory cytokines (Oberhoffer et al., 1999)–and albumin. This is further reinforced by the lower 
HDL–c observed at higher WCCs. Intriguingly, the role of granulocyte-monocyte colony-stimulating factor (GM-CSF) 
has been investigated as a potential cholesterol lowering agent (Nimer et al., 1988). Whether, increased production of 
GM–CSF to aid the production of white cells in sepsis may subsequently contribute to the acute drop in HDL–c 
remains unknown and is a possible area of further study.  
 In the patients newly diagnosed with TB (55%) we noted even greater reductions in HDL–c. There is limited 
data reporting on changes in plasma lipid and lipoproteins in active TB where initial reductions in TC, TG, LDL–c and 
HDL-c levels and subsequent recovery of lipid and lipoprotein levels following successful treatment occur (Taparia, 
Yadav et al. 2014). In the only reported study examining lipid profiles in HIV-infected patients with active TB from 
Ethiopia, HIV-infected patients had significantly lower TC, TG, LDL–c and HDL-c compared to the HIV negative 
groups(Gebremicael et al., 2017). To our knowledge, no other study has compared lipid or lipoprotein levels in HIV-
infected patients with newly diagnosed TB to TB negative HIV-infected controls. Regarding the role of cholesterol in 
TB there is inconsistency. Concern exists that cholesterol may be an energy source for Mycobacterium tuberculosis 
(MTB), however, cholesterol–rich diets have, in contrast, accelerated bacteriologic sterilization of MTB (Martens et al., 
2008; Akpovi et al., 2013). It is suggested that, following TB infection, macrophage activation, free radical release and 
lipid peroxidation reduces lipid and lipoprotein levels (Gebremicael et al., 2017). Interestingly, if compared to the LPS 
and LTA bacterial walls, MTB too has a lipid rich wall as lipid mycolic acids comprise 60% of the cell wall and other 
lipid constituents include: lipoarabinomannan, isoprenoid lipids and glycerophospholipids (Jackson 2014, Ghazaei 
2018). We postulate that the reduced HDL-c level in TB patients may result from elimination of the MTB cell wall via 
reverse cholesterol transport – similar to gram negative and positive bacteria, however, further research is necessary to 
elucidate this mechanism(Morin et al., 2015).   
 TDF is noted to have an intrinsic lipid lowering effect (Santos, Saumoy et al. 2015). Of interest, despite all 
patients in the healthy group using TDF compared to less than half amongst the septic group using TDF, we still note 
significant reductions in TC, LDL–c and HDL–c amongst the HIV–infected septic group. Suggesting, that the lipid 
lowering effect in the sepsis group should not be attributed to TDF. However, this is tempered by the lower CD4 count 
and fewer virally suppressed patients in the sepsis group which may have contributed to the lower lipid levels observed 
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in the septic compared to healthy group (Floris-Moore et al., 2006). Although a low CD4 count is shown to reduce 
HDL-c a South African study showed no association between reductions in TC or LDL–c and CD4 count (Dave  et al., 
2016). As such, reductions in TC or LDL–c and CD4 count may still be attributed to alterations in lipid metabolism in 
acute sepsis.  
 Our study is limited by a small sample size and a second lipogram following recovery from sepsis to 
demonstrate improvement in lipid and lipoprotein levels is lacking. The use of a non–fasting lipogram is a limitation 
but the practicalities of obtaining a fasting lipogram amongst acutely ill patients precluded this. Furthermore, we did 
not measure specific inflammatory cytokine levels. The absence of critically ill HIV positive control group without 
sepsis is a shortcoming of the study. Whilst, differences between the two groups with regards immunological status, 
viral load and TDF use may serve as confounders when comparing lipid results between the two groups. The greater 
use of protease inhibitors, which also elevate lipid levels (Melroe, Kopaczewski et al. 1999), may have also contributed 
to elevated lipids in the healthy groups. However, the difference in prevalence of PI use between the groups was not 
large. Furthermore, the small sample size of this study did not allow for the analysis of initial lipid results as markers of 




 In septic HIV-infected patients, we note: TC, LDL–c and HDL–c are significantly lower than well HIV– 
infected controls and are similar to those described in septic HIV negative patients, however, of note these changes 
were more marked amongst those with active TB–in particular reductions in HDL-c. Further studies are necessary to 
determine the use of HDL-c as a prognostic indicator in acute sepsis amongst those with HIV; to clarify its potential 
immunomodulatory mechanisms; and the potential therapeutic implications of HDL-c modification that could improve 
outcomes in acute sepsis and MTB infection.  
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